Ropinirol "KRKA" 4 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "krka" 4 mg depottabletter

krka sverige ab - ropinirolhydrochlorid - depottabletter - 4 mg

Ropinirol "KRKA" 8 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "krka" 8 mg depottabletter

krka sverige ab - ropinirolhydrochlorid - depottabletter - 8 mg

Ropinirol "Mylan" 0,5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "mylan" 0,5 mg filmovertrukne tabletter

mylan ab - ropinirolhydrochlorid - filmovertrukne tabletter - 0,5 mg

Ropinirol "Mylan" 1 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "mylan" 1 mg filmovertrukne tabletter

mylan ab - ropinirolhydrochlorid - filmovertrukne tabletter - 1 mg

Ropinirol "Mylan" 2 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "mylan" 2 mg filmovertrukne tabletter

mylan ab - ropinirolhydrochlorid - filmovertrukne tabletter - 2 mg

Ropinirol "KRKA" 2 mg depottabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "krka" 2 mg depottabletter

krka sverige ab - ropinirolhydrochlorid - depottabletter - 2 mg

Ropinirol "Mylan" 5 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ropinirol "mylan" 5 mg filmovertrukne tabletter

mylan ab - ropinirolhydrochlorid - filmovertrukne tabletter - 5 mg

Canesten 10 mg/g vaginalcreme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

canesten 10 mg/g vaginalcreme

bayer ab - clotrimazol - vaginalcreme - 10 mg/g

Canesten 100 mg vaginaltabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

canesten 100 mg vaginaltabletter

bayer ab - clotrimazol - vaginaltabletter - 100 mg

Tagrisso Den Europæiske Union - dansk - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - carcinom, ikke-småcellet lunge - andre antineoplastiske midler, protein kinase hæmmere - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.